Genetic modifiers of multiple sclerosis progression, severity and onset

Publication date: Available online 10 May 2017
Source:Clinical Immunology
Author(s): A. Dessa Sadovnick, Anthony L. Traboulsee, Yinshan Zhao, Cecily Q. Bernales, Mary Encarnacion, Jay P. Ross, Irene M. Yee, Maria G. Criscuoli, Carles Vilariño-Güell
The genetic contribution to clinical outcomes for multiple sclerosis (MS) has yet to be defined. We performed exome sequencing analysis in 100 MS patients presenting opposite extremes of clinical phenotype (discovery cohort), and genotyped variants of interest in 2016 MS patients (replication cohort). Linear and logistic regression analyses were used to identify significant associations with disease course, severity and onset. Our analysis of the discovery cohort nominated 38 variants in 21 genes. Replication analysis identified PSMG4 p.W99R and NLRP5 p.M459I to be associated with disease severity (p=0.002 and 0.008). CACNA1H p.R1871Q was found associated with patients presenting relapsing remitting MS at clinical onset (p=0.028) whereas NLRP5 p.M459I and EIF2AK1 p.K558R were associated with primary progressive disease (p=0.031 and 0.023). In addition, PSMG4 p.W99R and NLRP5 p.R761L were found to correlate with an earlier age at MS clinical onset, and MC1R p.R160W with delayed onset of clinical symptoms (p=0.010–0.041).



http://ift.tt/2pAezLs